Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults.

ABSTRACT:

Background

Studies comparing dipeptidyl peptidase-4 inhibitors (DPP4Is) to sulfonylureas (SUs) are unavailable for frail older adults, especially nursing home (NH) residents. We examined the effects of DPP4Is versus SUs on severe adverse glycemic events, cardiovascular events, and death among NH residents.

Methods

We conducted a national retrospective cohort study of long-stay NH residents aged ≥65 years using 2008-2010 national US Minimum Data Set clinical assessment data and linked Medicare claims. Exposure was new DPP4I versus new SU use assessed via Medicare Part D drug claims. One-year outcomes were severe hypoglycemia, severe hyperglycemia, acute myocardial infarction (AMI), heart failure (HF), major adverse cardiovascular events plus HF (MACE+HF), and death. We compar

SUBMITTER: Zullo AR 

PROVIDER: S-EPMC8497422 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature